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Abstract
Prader-Willi Syndrome (PWS), a maternally imprinted disorder and leading cause of obesity,
is characterised by insatiable appetite, poor muscle development, cognitive impairment,
endocrine disturbance, short stature and osteoporosis. A number of causative loci have been
located within the imprinted Prader-Willi Critical Region (PWCR), including a set of small
non-translated nucleolar RNA’s (snoRNA). Recently, micro-deletions in humans identified
the snoRNA Snord116 as a critical contributor to the development of PWS exhibiting many
of the classical symptoms of PWS. Here we show that loss of the PWCRwhich includes
Snord116 in mice leads to a reduced bone mass phenotype, similar to that observed in
humans. Consistent with reduced stature in PWS, PWCR KOmice showed delayed skeletal
development, with shorter femurs and vertebrae, reduced bone size and mass in both sexes.
The reduction in bonemass in PWCR KOmice was associated with deficiencies in cortical
bone volume and cortical mineral apposition rate, with no change in cancellous bone. Impor-
tantly, while the length difference was corrected in aged mice, consistent with continued
growth in rodents, reduced cortical bone formation was still evident, indicating continued
osteoblastic suppression by loss of PWCR expression in skeletally mature mice. Interest-
ingly, deletion of this region included deletion of the exclusively brain expressed Snord116
cluster and resulted in an upregulation in expression of both NPY and POMCmRNA in the
arcuate nucleus. Importantly, the selective deletion of the PWCR only in NPY expressing
neurons replicated the bone phenotype of PWCR KOmice. Taken together, PWCR deletion
in mice, and specifically in NPY neurons, recapitulates the short stature and low BMD and
aspects of the hormonal imbalance of PWS individuals. Moreover, it demonstrates for the
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first time, that a region encoding non-translated RNAs, expressed solely within the brain, can
regulate bone mass in health and disease.
Introduction
Prader-Willi syndrome (PWS), initially described in 1956 [1], is a neurological disorder with a
number of clinical symptoms that greatly impair an individual’s standard of living, most
characteristically excessive hunger and marked obesity. The main features of the PWS pheno-
type are more broad, and include: hypotonia, hyperphagia, hypogonadism, motor development
issues, cognitive impairment, growth hormone (GH) deficiency, dysmorphic features and
behavioural issues [2]. Importantly, PWS patients also exhibit a marked bone phenotype, with
reduced stature, low bone mineral density (BMD) and scoliosis [3–5].
The genetic basis for PWS results from the inactivation of the Prader-Willi Critical Region
(PWCR), q11-q13 region on paternal chromosome 15 [6], which contains a cluster of
imprinted genes. The PWCR region on the maternal chromosome is imprinted and therefore
epigenetically silenced through methylation, leading to mono-allelic expression of the pater-
nal genes [6]. Interstitial deletions (65–70%), maternal uniparental disomy (20–30%) and
mutations within the imprinting centre (2–5%) account for most PWS cases [2, 6]. Adding to
the complexity, the PWCR contains several clusters of C/D box snoRNAs (small nucleolar
RNAs) [7–10], which are located within the introns of the SNURF-SNRPN gene, which
resides in this region. These snoRNA transcripts get processed and released during the matu-
ration of the SNURF-SNRPN transcript. One of these snoRNA clusters in humans is the
HBII-85 (SNORD116) region containing 29 tandem repeats of SNORD116 that are widely
expressed in the brain [11]. SnoRNAs gain functionality as a result of protein association to
give rise to small nuclear ribonucleoproteins (snRNPs), which interact with target RNAs
through base pair interactions.
The targets of the snoRNA, SNORD116, remain elusive; however it has been implicated in
the aetiology of PWS. Several cases of microdeletion only affecting the SNORD116 cluster
have been identified in humans, all of which gave rise to aspects of the classical clinical mani-
festations of PWS [6]. Importantly, PWCR knockout mice bear many of the phenotypic
symptoms of PWS individuals like the significant increase in food intake so typical for
PWS [12]. However, to date the effect of loss of the PWCR on skeletal tissue has not been
determined.
Prepubertal PWS children have normal BMD (when adjusted for their short stature) [13–
15], but during adolescence and adulthood, they have reduced total BMD and bone mineral
content (BMC) likely due to lack of bone mineral accrual [3–5]. As a result, osteoporosis is
prevalent in PWS individuals, who also face other orthopaedic complications associated with
their weight gain, including scoliosis, kyphosis, hip dysplasia and fractures [4, 16]. The causes
for this reduced BMD have been linked to reduced levels of growth hormone (GH) and hypo-
gonadism [4]. However, GH treatment on PWS children did not increase BMD despite
increases in height SD-scores, indicating that other factors are involved [13]. Further studies
are required to investigate the cause of the PWS skeletal phenotype including the genes known
to be involved in PWS such as Snord116. The aim of this study was therefore to examine the
effects of PWCR deficiencies on bone homeostasis in mice.
PWCRRegulates Bone Mass
PLOS ONE | DOI:10.1371/journal.pone.0148155 January 29, 2016 2 / 17
Materials and Methods
Animals
All research and animal care procedures were approved by the Garvan Institute / St Vincent’s
Hospital Animal Experimentation Ethics Committee and conducted in accordance with the
Australian Code of Practice for the Care and Use of Animals for Scientific Purpose. Mice were
housed under conditions of controlled temperature (22°C) with a 12h light, 12h dark cycle
(lights on at 0700 h). Mice were fed a normal chow diet ad libitum (8% calories from fat, 21%
calories from protein, 71% calories from carbohydrate, 2.6 kcal/g; Gordon’s Speciality Stock
Feeds, Yanderra, New South Wales, Australia). Water was available ad libitum for all mice.
C57Bl/6JAusb PWCR floxed mice [12] were obtained from Jackson Laboratory and heterozy-
gous mice were bred to homozygosity (PWCR KO) and the additional resulting WT littermates
were used as controls. Mice with the selective deletion of PWCR in NPY expressing neurons
were generated as described previously [17]. Briefly, floxed PWCR mice (PWCRlox/lox) were
crossed with a C57Bl/6JAusb transgenic line that drives Cre gene expression under the control
of the NPY promoter (NPYcre/+) to generate double heterozygous mice (PWCRlox/+/ NPYcre/+).
These mice were then crossed again with PWCRlox/lox mice to generate PWCRlox/lox/NPYcre/+
mice and controls.
Bone densitometry and body composition analysis
Bone mineral content (BMC), bone mineral density (BMD) were measured on excised mouse
femur bones, using a dedicated mouse dual energy X-ray absorptiometer (DXA) (Lunar Pixi-
mus II, GE Medical Systems, Madison WI), as previously described [18].
Micro Computed Tomography
Skyscan 1174 scanner and analysis software (Skyscan, Aartselaar, Belgium) were used to exam-
ine 3-dimensional cortical bone structure and cancellous bone microstructure, as previously
described [19]. Following fixation, bone was packed into an enclosed rigid plastic tube filled
with 70% ethanol. Distal femora were scanned at 6.2um pixel size. The image projections were
reconstructed using NRecon software (Skyscan) and the reconstructed images were aligned
using Dataviewer software (Skyscan).
Analysis of the cancellous bone was carried out in 150 slices (0.93mm) selected at 40 slices
(0.248mm) from the distal femoral growth plate. Cortical bone analysis was carried out in 150
slices selected at 600 slices (3.72 mm) proximal from the distal femoral growth plate. Whole
bone analysis considered all the bone as an ROI. CT-Analyzer software (Skyscan) was used.
For vertebrae, the osteo-cartilage junction at the growth plate was the landmark at each end
of the third lumbar vertebral body. Slices between the rostral and caudal landmarks were
selected, with 10 slices offset from the rostral and 25 slices offset from the caudal landmark.
Vertebral bodies in the selected slices were then separated from the vertebral processes using
an elliptical region of interest. This isolated vertebral body was then subdivided into cancellous
and cortical parts by manual tracing. Cancellous bone volume was generated for the cancellous
region of the third lumbar vertebral body.
Tissue collection and bone histomorphometry
Upon completion of the study, mice were culled at 16- or 35-weeks of age by cervical dislocation.
For bone analysis both femora were excised and fixed in 4% PBS-buffered paraformalde-
hyde for 16h at 4°C. The right femora were bisected transversely at the midpoint of the long
PWCRRegulates Bone Mass
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axis. After dehydration, distal halves were embedded un-decalcified in methyl-methacrylate
(Medim-Medizinische Diagnostik, Giessen, Germany).
Sagittal sections of 5 μm thickness were stained and evaluated as previously described [20].
Analysis of cancellous bone volume (BV/TV, %), trabecular thickness (Tb.Th, μm), and num-
ber (Tb.N, /mm) was carried out on sections stained with modified von Kossa for mineralized
bone. To access bone formation indices, mice were given subcutaneous injections of the fluo-
rescent compound calcein (Sigma Chemical Company, St Louis, USA), 20 mg/kg at 7 and 3
days prior to collection. Mineralizing surface (MS, %) and mineral apposition rate (MAR, μm/
d) were measured from unstained sections and bone formation rate (BFR = MS/BS  MAR,
μm3/μm2/d) were calculated. Bone resorption indices—osteoclast surface (Oc.S, %) and num-
ber (Oc.N, /mm), were estimated in tartrate-resistant acid phosphatase stained sections [21].
All cancellous measurements were conducted in a sample area bordering the epiphyseal growth
plate, beginning 0.25 mm proximal to the mineralization zone to exclude primary spongiosa
and extending proximally 4.2 mm, encompassing all the cancellous bone within the cortices, as
described previously [22]. Cortical mineral apposition rate was measured at the mid-point of
the shaft on the posterior endosteal surface in a region 1000 μm proximal from the mid femora
[23].
Primary osteoblast cultures
Bone marrow mesenchymal stromal cells (BMSCs) were isolated by flushing femur and tibia
bones with a 23-gauge needle syringe into complete α-MEM (10% FCS, 100U/ml PenStrep, 1x
GlutaMax) and cultured in T-75 flasks. Non-adherent cells were discarded through media
changes. BMSCs were seeded at 6 x 104 cells/well in 24-well plates and cultured with 50ug/ml
Ascorbic acid and 5mM β-Glycerophosphate for 14 days. Cells were fixed in cold 90% Ethanol
for 15 minutes and stained with Alizarin Red for mineralized nodules. Mineralized area was
quantified from a color scan of the stained culture plates using Adobe Photoshop CS5.1
(Adobe) for thresholding and ImageJ software (http://rsb.info.nih.gov/ij/) for particle analysis.
Alkaline phosphatase assay
Alkaline phosphatase activity was determined by using alkaline phosphatase assay kit (Cat#
ab83369, ABCAM) following manufacturer’s instructions. In brief, culture medium at day 14
from primary osteoblast cultures of wild-type and PWCR KO was collected. Triplets of 25μl of
each sample were added into 96-wells and 50 μl of assay buffer was added, followed by 50 μl of
the 5 mM pNPP solution. The reaction was stopped by adding 20 μl of stop-solution for back-
ground control. Standard curves were generated as manufacturer’s guide. The alkaline phos-
phatase enzyme activity of each sample was calculated based on the comparison between
standard curve and sample curve, and was shown as Unit/ml (U/ml).
Analysis of gene expression
RNA was isolated from cleaned tibiae using TRIzol reagent as per the manufacturer’s instruc-
tions. Real-time polymerase chain reaction was used to determine gene expression of osterix,
osteocalcin, Runx-2, alkaline phosphatase, receptor activator of nuclear factor kappa-B
ligand (Rankl), osteoprotegerin (Opg), and the housekeeping genes β-actin, Gapdh (Taq-
Man Gene Expression assays for Runx-2, alkaline phosphatase, Rankl, Opg from Applied
Biosystems, Foster City, CA). Primer sequences for osterix, osteocalcin, Gapdh are as follows:
osteocalcin (sense: 50-TTCTGCTCACTCTGCTGACCCT-30, antisense:50-
CCTGCTTGGACATGAAGGCTT-30), osterix (sense: 50-AGAGGTTCACTCGCTCT
GACGA -30, anti sense: 50-TTGCTCAAGTGGTCGCTTCTG-30), Gapdh (sense:
PWCRRegulates Bone Mass
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50-GCATCTCCCTCACAATTTCCA-30, antisense:50-GTGCAGCGAACTTTATTGAT
GG-30). cDNA synthesis was performed with 0.5–1 μg of total RNA with oligo(dT)20 by
using the SuperScript III First-Strand Synthesis System for reverse transcription-PCR (Invi-
trogen). Real-time polymerase chain reaction reactions were performed using the TaqMan
Universal PCR master mix and Power SYBR Green PCR Master Mix (Applied Biosystems) in
an ABI Prism 7900 HT sequence detector (Applied Biosystems).
Primary osteoclast cultures
Mouse bone marrow cells were used for the osteoclast formation assay. Briefly, 10-week-old
female wild-type and PWCR KOmice were sacrificed by cervical dislocation, and marrow was
flushed from tibias supplemented with 10% FBS, 150 μg/ml penicillin, 125 μg/ml streptomycin,
1.25 μg/ml Fungizone. Cleaned tibias were used for RNA isolation as described below.
The bone marrow cell suspension was aspirated through a 21-gauge needle and filtered
with a 100-μm-pore-size cell strainer filter (Falcon/Becton Dickinson, Franklin Lakes, NJ).
Cells were then washed twice in culture medium and centrifuged for 10 min at 200×g, and
1 × 105cells/cm2 were plated in 96-well flat-bottom tissue culture-treated plates (Costar, Cam-
bridge, MA, USA) in 150 μl of culture medium containing 30 ng/ml recombinant murine
M-CSF (R&D Systems, Minneapolis, MN, USA) and 20 ng/ml recombinant murine RANKL
(RANKL-TEC, R&D Systems, Minneapolis, MN, USA). Culture medium was refreshed after 3
days. After 7 days of co-culture, cells were fixed in 4% formaldehyde in PBS for 10 min. Fixed
cells were washed with PBS and stained for tartrate-resistant acid phosphatase (TRACP)
according to the manufacturer’s instructions (Sigma). The number of TRACP-positive multi-
nucleated (three or more nuclei per cell) and mononuclear cells were counted with a Leica DM
IL microscope (Leica, Wetzlar, Germany) equipped with a ×20 objective.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 6.00, statistically significant values
were those with p values less than 0.05. All data are expressed as a mean ± standard deviation
(SD). Within gender, across genotype comparisons were carried using student’s T test.
Results
Lack of PWCR in mice reduces bone mass specifically affecting cortical
bone
DXA analysis of excised femurs from 16 week old male and female PWCR KOmice revealed a
marked bone phenotype in both genders, with femoral BMD and BMC significantly reduced
compared to age- and sex-matched wild type mice (WT) (Fig 1A and 1B). These changes were
consistent with a reduction in femur length (Fig 1C) in both genders of PWCR KOmice.
In order to investigate whether the bone phenotype extended beyond a reduction in bone
length; the entire femur was scanned by μCT, illustrating a generalized reduction in cross-sec-
tional bone area in the diaphysis of KO femurs (Fig 2A). Detailed μCT analysis demonstrated
reductions in periosteal and endosteal perimeter at the diaphysis in both sexes (Fig 2B and 2C).
The reduced cortical dimensions were accompanied by reduced cortical bone volume and cor-
tical thickness in PWCR KO femurs (Fig 2B and 2C). In contrast, analysis of cancellous bone
by μCT in intact femurs (Fig 2F), and analysis of von kossa stained sagittal femoral sections by
histomorphometry (Fig 2G), revealed no difference in the micro-architecture of cancellous
bone between WT and PWCR KO.
PWCRRegulates Bone Mass
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To determine whether the diminished cortical production in PWCR KOmice was a gener-
alised effect, we examined the axial skeleton. Vertebral length (L3 vertebrae) was reduced in
male PWCR KOmice, with a similar but non-significant reduction in females (Fig 3A and
3B). Recapitulating the femoral changes, cortical bone volume was reduced in PWCR KO
relative to WT mice, with cortical thickness significantly reduced in female KO mice only
Fig 1. Whole bone analysis of PWCRKOmice. Femurs from 16 week old male and female PWCR KO and
WTmice were dissected and analysed by DXA and measured for length. A.) BMD; B.) BMC and C.) femur
length. n = 7–10 represented as mean ± SD. * p-value<0.05, ** p-value<0.01, *** p-value<0.001.
doi:10.1371/journal.pone.0148155.g001
PWCRRegulates Bone Mass
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Fig 2. Cortical bone analysis of PWCRKOmice. A.) Whole bone analysis of male and female femurs of PWCRKO andWTmice using micro CT. Micro
CT analysis of cortical bone on a standardised region of the femur diaphysis :- B.) periosteal circumference; C.) endosteal circumference; D.) cortical bone
volume; and E.) cortical thickness. F.) Micro CT analysis of cancellous bone of the distal femur. G.) Representative images and histomorphometric analysis
of sagittal femoral cancellous bone volume. n = 7–10 represented as mean ± SD. * p-value<0.05, ** p-value<0.01, *** p-value<0.001.
doi:10.1371/journal.pone.0148155.g002
PWCRRegulates Bone Mass
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(Fig 3C and 3D). Vertebral cancellous bone volume was unchanged between WT and KO
mice (Fig 3E).
Lack of PWCR reduces bone formation and osteoblast differentiation,
without alterations in osteoclastogenesis
The reductions in bone length and size indicate the existence of a developmental effect occur-
ring in PWCR KO mice, consistent with the reduced stature evident in PWS. However, given
the ongoing skeletal issues in PWS, we sought to determine whether the skeletal effects of
Fig 3. Lumbar vertebral bone analysis of PWCRKOmice. A.) Representative images and micro CT analysis of L3 vertebral bone :- B.) Vertebral length;
C.) cortical bone volume; D.) vertebral cortical thickness; E.) cancellous bone volume. n = 7–10 represented as mean ± SD. * p-value<0.05, ** p-value<0.01.
doi:10.1371/journal.pone.0148155.g003
PWCRRegulates Bone Mass
PLOS ONE | DOI:10.1371/journal.pone.0148155 January 29, 2016 8 / 17
PWCR extended beyond growth. In order to compare the bone cell activity in adult mice with
the architectural changes evident in PWCR KOmice, we examined bone formation indices in a
region corresponding to previous μCT analysis in the femora. This region constitutes part of
the modelling drift responsible for dimensional changes in mature lone bones [24], and as such
in sagittal sections this surface is consistently covered by bone formation. Importantly, analysis
of double fluorochrome labelling in 16 week old mice, showed a marked decrease in periosteal
MAR in both genders of PWCR KOmice (Fig 4A). This result indicated that loss of the PWCR
was capable of altering bone formation in mature mice, and illustrates an effect beyond regula-
tion of developmental processes. Consistent with the observed reductions in growth and bone
size, ongoing anti-anabolic actions, and previous publications [12], serum IGF-1 levels were
markedly reduced in PWCR KO compared to wild type (Fig 4B). To investigate whether the
deficiencies in bone mass were due to an intrinsic defect in osteoblast activity, PWCR KO bone
marrow stromal cells (BMSC) were differentiated to osteoblasts ex vivo and their properties
investigated. Alizarin red staining, as a marker of mineralisation was reduced at day 21 of cul-
ture in PWCR KO osteoblast cultures compared to WT, alkaline phosphatase activity in the
culture medium was reduced at day 14 (Fig 4C). Gene expression for markers of mature osteo-
blasts were reduced in cortical bone from PWCR KOmice, with Osterix, alkaline phosphatase
and osteocalcin reduced, albeit with unchanged Runx2 (Fig 4D). The osteoblast-specific nature
of the PWCR KO phenotype was determined by examining osteoclastic development in vitro.
Osteoclast cultures from PWCR KO bone marrow monocytes (BMMs) showed equivalent pro-
duction of TRAP+ multinucleated cells after RANKL treatment compared to WT (Fig 4E),
indicating no effect upon osteoclastic potential by Snord116. The osteoblastic stimulation of
osteoclastogenesis was also unaltered in PWCR KOmice, with RANKL and OPG production
by osteoblasts not different between PWCR KO andWTmice (Fig 4F).
PWCR knockout bone phenotype persists with age
Since PWS is characterised by impaired early development, and having demonstrated impaired
bone formation after skeletal maturity, we examined whether this would be corrected in later
life. Interestingly, in contrast to 16-week-old mice, femur length was not different between
male WT and KOmice at 35 weeks of age (Fig 5A), consistent with the lack of growth plate clo-
sure in mice. Importantly, despite the correction of femur length, 35-week-old KO mice
retained a significant reduction in femoral BMC (Fig 5C), although DXA analysis revealed sim-
ilar BMD as that in WT mice (Fig 5B), suggesting reduced bone size in KO mice. Indeed, simi-
lar to the 16-week-old bone phenotype, cortical bone volume and cortical thickness were
significantly reduced in the femurs of 35-week-old PWCR KOmice (Fig 5C). Importantly,
IGF-1 was still markedly reduced in PWCR KOmice at this age (Fig 5E). Similarly to younger
mice, cancellous bone volume was not different between 35 week old PWCR KO andWTmice
(data not shown). Thus loss of PWCR expression results in long-term deficits in cortical bone
accrual.
Selective deletion of the PWCR only in NPY neurons replicates the
PWCR KO bone phenotype
As Snord116 expression is confined to the brain [25, 26], the reduction in bone formation most
likely reflects alterations in signalling from the central nervous system. Neuropeptide Y (NPY)
is a classic neuronal regulator of energy homeostasis and has also been shown to play an impor-
tant role in the regulation of bone formation [18]. Therefore, we investigated the mRNA
expression levels of NPY and the counter-regulatory proopiomelanocortin (POMC) in the
arcuate nucleus of PWCR KO andWTmice by in situ hybridisation. Interestingly, the
PWCRRegulates Bone Mass
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Fig 4. Bone cell activity and expression analysis of PWCRKOmice. A.) Bone histomorphometric analysis of double fluorochrome labelled femur
sections showing Mineral Apposition Rate (MAR). n = 6–10 represented as mean ± SD. B.) Serum IGF-1. C.) Alizarin red staining in bone marrow stromal
cells (BMSCs) cultured fromWT and PWCR KO femur and tibia bones, after 14 days in osteogenic medium; Mineralized area; Alkaline phosphatase activity
in culture media. D.) Expression of osteoblast markers in bone isolates from biological replicates of 16 week old mice:- Runx2; Osterix; Alkaline phosphatase;
Osteocalcin. E.) Osteoclast cultures frommarrow of WT and PWCR KOmice:- representative images; TRAP+multinuclear cell number. F.) RANKL and
OPG expression in bone isolates from biological replicates of WT and PWCRKOmice. n = 4 represented as mean ± SEM. * p-value<0.05, ** p-value<0.01,
*** p-value<0.001.
doi:10.1371/journal.pone.0148155.g004
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expression levels of both NPY and POMC were significantly increased in the PWCR KOmice
(Fig 6A and 6B). This disruption to the normally observed counter-regulatory pattern of NPY
and POMCmRNA expression suggests that the inhibiting projections from NPY neurons to
POMC neurons do not function in the normal way in the absence of the PWCR. Previous stud-
ies elevating NPY expression solely in the arcuate nucleus have demonstrated a marked sup-
pression of osteoblast activity on cortical bone surfaces [18].
In order to determine whether these neuronal alterations are driving the bone phenotype of
PWCR KOmice, we investigated the bone phenotype of male mice with a specific deletion of
the PWCR only in NPY neurons (PWCRf/f, NPYCre/+) [17]. As shown in Fig 6C–6E, similar to
PWCR KOmice, PWCRf/f, NPYCre/+ mice display significantly reduced whole body BMD,
BMC and femoral length compared to controls. Furthermore, selective deletion of the PWCR
from NPY neurons resulted in a cortical bone phenotype similar to that of germline PWCR
KOmice with a significant reduction in cortical bone volume as well as periosteal and endos-
teal perimeter with no change in cortical thickness (Fig 6F–6I).
In order to confirm and further investigate the direct influence of the PWCR on NPY neu-
rons we measured serum IGF-1 levels and performed in situ hybridisation. Although serum
IGF-1 levels were unchanged (Fig 6J), both arcuate nuclei NPY and POMCmRNA expression
were significantly upregulated (Fig 6K and 6L) identical to the global deletion model. Taken
together, these data indicate a critical role of the PWCR in NPY neuronal function and the reg-
ulation of bone mass.
Fig 5. Bone characterisation of aged PWCRKOmice. A.) Femur length of 35 week old male WT and PWCR KOmice; B.) BMD and C.) BMCmeasured by
DXA of isolated femurs; Three-dimensional μCT analysis of cortical and cancellous bone D.) cortical bone volume; E.) cortical thickness; F.) IGF-1 n = 6
represented as mean ± SD. ** p-value<0.01, *** p-value<0.001.
doi:10.1371/journal.pone.0148155.g005
PWCRRegulates Bone Mass
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Fig 6. Selective deletion of PWCR only in NPY neurons. In situ hybridisation for A.) NPY and B.) POMC
expressions in arcuate nucleus of WT and PWCR KOmice. Bone phenotype analysis of PWCRf/f, NPYCre/+
and PWCRf/f control mice: C.) femur length; D.) whole body BMD; E.) whole body BMCmeasured by DXA;
F.) cortical bone volume; G.) cortical thickness; H.) periosteal circumference and I.) endosteal circumference
measured by μCT. n = 6–8 represented as mean ± SD using 16 week old male mice. J.) Serum IGF-1 levels
and in situ hybridisation for K.) NPY and L.) POMC in the arcuate nucleus of PWCRf/f, NPYCre/+ and PWCRf/f
PWCRRegulates Bone Mass
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Discussion
In this study we demonstrate the critical role of the PWCR which contains the Snord116 cluster
in the regulation and maintenance of bone mass, and thereby identify the first pathway from
the brain to bone mediated by a region encoding non-translated RNAs, and suggest a putative
role for this in human disease. The analysis of mice deficient in the PWCR revealed a skeletal
phenotype that shows strong parallels with that found in humans with PWS. In particular, lack
of the PWCR led to a reduction in the length of long bones (femur) and vertebral bodies in
skeletally mature animals, however, this was corrected when mice reached an older age, consis-
tent with non-closure of growth-plates in rodents. Importantly, both mature and aged mice
displayed a significant reduction in cortical bone formation and cortical bone size, indicating a
prolonged action of the PWCR in skeletal homeostasis. These changes were coincident with
reduced serum IGF-1 levels, indicating a long-term disruption of the somatotropic axis. Con-
sistent with the restriction of Snord116 expression to the brain; we identify the PWCR in NPY
neurons as critical to the pathway to bone, highlighting the central nature of the PWCR signal-
ling axis. PWCR deletion led to an upregulation in both NPY and POMC expression levels in
the arcuate nucleus, a surprising finding given that NPY and POMC normally show opposing
expression levels in response to situations of positive or negative energy balance. Selective
deletion of the PWCR only in NPY neurons was sufficient to replicate the bone phenotype of
germline PWCR KOmice, without any alteration in circulating IGF-1 levels, as well as the
deregulated simultaneous upregulation of both NPY and POMC levels. This model also has
similarities to the skeletal phenotype of mice with specific overexpression of NPY in the arcuate
[27]. In this manner, the PWCR KOmice provide a novel model to study the skeletal defects in
PWS through both endocrine and neural pathways. Moreover, the identification of a region
encoding non-translated genes regulating bone mass reveals a new level of complexity involved
in the central regulation of bone mass.
In patients with PWS, short stature and reduced BMD are commonly observed, along with
growth hormone deficiency, [3, 14], however, the precise mechanism involved in these changes
has yet to be defined. The short stature and low BMD have been linked to a lack of sufficient
GH production [13]. GH supplementation remains one of the front line therapies for both
body composition and skeletal abnormalities in PWS, most commonly in infants/children but
also in adults [28]. However, GH treatment on PWS children had no long-term effects on
BMD, indicating that other factors are also involved [13]. The reduction in the downstream
effector of GH, IGF-1, observed in PWCR KOmice in the current, and previous studies [12] is
consistent with the GH deficiency observed in PWS and highlights the potential to better define
the disease process in PWS. Mouse genetic models have produced a detailed understanding of
the effects of IGF-1 and GH deficiency on the skeleton. GHRH receptor, GH receptor and liver
specific IGF-1 (LID) knockout mouse models reduce the circulating pool of IGF-1 but not skel-
etally produced IGF-1, leading to a reduction of cortical parameters but leaving cancellous
bone unchanged [29]. This scenario is parallel to what appears to be evident in the PWCR KO
mice, with alterations of central PWCR expression in the hypothalamus disrupting the central
somatotropic axis, reducing circulating IGF-1 levels. In addition, while not as similar as the
present model, GH receptor KO and IGF-1 KO mice also show significantly reduced periosteal
mineral apposition rates [30, 31]. It is important to note that PWCR KOmice are not complete
photocopies of PWS, particularly in body composition. Despite hyperphagia, KO mice are
control mice. n = 4–6 represented as mean ± SD using 16 week old male mice. * p-value<0.05, ** p-
value<0.01, *** p-value<0.001.
doi:10.1371/journal.pone.0148155.g006
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leaner and lighter at younger ages, although this is corrected with age [12]. One other hormone
that has been implicated in the phenotype of PWS is ghrelin. However, no obvious changes in
ghrelin serum levels have been observed in our model [17], suggesting this hormone seems less
likely to play a role in the observed bone phenotype of PWCR deficient mice. However, the
consistency of the skeletal changes in the PWCR KOmouse represent an important opportu-
nity to increase our understanding of PWS, and also highlights the potential complexity of the
regulatory processes involved in the disease aetiology.
The reduction in BMD in PWCR KOmice was attributable to a cortical-specific phenotype
evident in both axial and appendicular bone. In the femur, PWCR deficiency reduced endosteal
and periosteal circumferences, with reduced cortical bone volume also evident in the vertebrae.
These reductions in dimension were retained even when linear differences were absent in aged
mice. Interestingly, cancellous bone mass and architecture were normal in KO mice. The
growth retardation indicated by reduced femoral and vertebral length at 16 weeks contributed
to the observed deficits in cortical bone mass during early development of PWCR KOmice.
However, the reduction in mineral apposition in aged mice (35 weeks), when length differences
were absent, implies that the PWCR continues to exert effects on bone homeostasis beyond
development. Femur length was corrected with age, which is likely associated with the lack of
closure of murine compared to human growth plates. However, the low bone mass phenotype
was maintained, and demonstrated signs of exacerbation, with cortical area and thickness sig-
nificantly reduced in male PWCR KOmice at 35 weeks, but not at 16 weeks. Thus PWCR
action is required for both development and maintenance of bone mass throughout life. That
such a region containing non-translated RNAs, expressed solely within the brain and from an
imprinted region such as the PWCR, can exert substantial and life-long effects upon bone
homoeostasis illustrates a new level of complexity of skeletal regulation.
The hypothalamus is known to play a major role in the development of pathologies in PWS.
Snord116 is exclusively expressed in the brain of mice, with high expression in the hypothala-
mus [25, 26]. Given the known role of central NPY in the regulation of bone mass and the
observed upregulation of NPY and POMC expression in the arcuate nucleus of PWCR KO
mice, mice with selective deletion of the PWCR only in NPY neurons were investigated [17].
These mice almost exactly replicated the alterations in bone mass, femoral length, and NPY/
POMC expression levels seen in the germline PWCR KOmice, without alterations in IGF-1
levels. This highlights the importance of this population of neurons and their critical role in the
bone phenotype of PWS. The changes seen in NPY and POMCmRNA, which are both upregu-
lated in these mice, are surprising since they normally show opposing expression levels in
response to situations of positive or negative energy balance. It has been clearly established that
NPY has the dominant role in this counter regulatory process and high NPY levels would nor-
mally cause the down-regulation of POMCmRNA. The fact that this is not the case in this
model suggests a vital connection or functional response is missing when there is a lack of the
PWCR. Mice lacking NPY have an anabolic bone phenotype in both cortical and cancellous
compartments characterised by elevated bone formation, whilst in contrast, viral-mediated ele-
vation of hypothalamic NPY levels in wildtype mice results in a reduction in bone formation
despite increased body weight [18]. Mechanistically, NPY has been shown to exert these effects
through regulating the differentiation of osteoblast precursors as well as the action of mature
osteoblasts [21, 32]. The fact that the PWCR deletion led to upregulated NPY levels and
changes in cortical bone mass and bone formation without changes in cancellous bone mass,
may be due to the deregulated counter-regulatory response between NPY and POMC expres-
sion levels, but also highlight that direct neuronal actions may contribute to the observed bone
phenotype.
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Little is known about Snord116 other then that it is a C/D box snoRNA exclusively
expressed in mouse brains [25]. These C/D box snoRNAs are involved in methylation by inter-
acting, through base pairing, with ribosomal RNA (rRNA) or small nuclear RNA (snRNA)
[33]. Our appreciation of the important role non-translated species play in physiological pro-
cesses is in its infancy, particularly with regard to functional studies. Moreover, our under-
standing of RNA control of bone is confined to microRNA species within the bone micro-
environment [34]. Thus, the PWCR model may represent the first non-local, non-translated
regulator of bone to be identified. The growing premise that Snord116 regulates the somatotro-
pic axis as well as neuronal output to peripheral tissues may have important implications for
PWS. The pituitary and hypothalamus are the centres of the growth hormone axis and are
thought to be affected in PWS, and GH supplementation is a front line therapy [35, 36].
Indeed, Snord116 is highly expressed in these regions and knockout mice display other charac-
teristics of pituitary-hypothalamus dysfunction such as delayed sexual maturation in female
mice and hyperphagia [12]. Interestingly, it was reported that PWCR KOmice have normal
pituitary and normal numbers of GH expressing neurons, indicating a defect in the hypotha-
lamic control of GH release [12]. This is reinforced by the reduced IGF-1 levels in this study.
However is also important to keep in mind that Snord116 is being produced as a cleavage
product out of intronic sequences of the large SNURF-SNRPN transcripts and the deletion of
the PWCR removes the Snord116 cluster as well as approximately 150kb of genomic sequence,
including some of the exons of the SNURF-SNRPN transcripts. It is therefore possible that
alterations to the SNURF-SNRPN or long U-Ube3A antisense transcripts contained within this
region could have contributed to an altered function of NPY neurons.
In conclusion, this study provides evidence that regulation of the PWCR also containing the
non-translated snoRNA, Snord116 in the hypothalamus plays a marked role in development
and maintenance of cortical bone mass and structure, through regulation of longitudinal
growth and periosteal and endosteal bone formation. Bone homeostasis is disrupted by dele-
tion of the PWCR, and this can be traced to altered actions in NPY neurons, supporting brain-
bone regulation by non-coding RNAs and clarifying the complex phenotype of PWS. As such,
this represents the first report of a central, RNA-mediated pathway to bone. Moreover,
Snord116 expression plays a causal role in the bone phenotype of PWS individuals. While the
germline knockout model does not completely reproduce the human PWS, it does highlight
the significant contribution of the PWCR to the observed human phenotype as also seen in
some behavioural aspects [37]. The PWCR KOmouse represents an important tool for study
of the complex aetiology of PWS.
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